Trial Profile

LOREA: ANALYSIS OF THE EFFECTIVENESS AND SAFETY OF LORLATINIB IN UNTREATED ALK-POSITIVE NSCLC PATIENTS IN A FRENCH REAL-WORLD CONTEXT

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 28 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lorlatinib (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms LOREA
Sponsors Pfizer

Most Recent Events

25 Mar 2025 Status changed from not yet recruiting to recruiting.
08 Nov 2024 Study type changed from Observational to interventional, hence design was changed to open-label and the protocol was amended.
08 Nov 2024 Planned initiation date changed from 15 Jul 2024 to 29 Nov 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com